Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Patent
1997-04-08
1999-06-29
Moezie, M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
514653, 514654, A61K 31135
Patent
active
059169230
ABSTRACT:
This invention provides a method of treating obesity, generalized anxiety disorder, post-traumatic stress disorder, late luteal phase disphoric disorder (premenstrual syndrome), attention deficit disorder, with and without hyperactivity, Gilles de la Tourette syndrome, bulimia iervosa or Shy Drager Syndrome in a mammal by administering to the mammal an effective amount of a hydroxycycloalkanephenethyl amine of the following structural formula: ##STR1## in which A is a moiety of the formula ##STR2## where the dotted line represents optional unsaturation;
REFERENCES:
patent: 4535186 (1985-08-01), Husbands et al.
patent: 4609758 (1986-09-01), Husbands
patent: 4611078 (1986-09-01), Husbands et al.
patent: 4761501 (1988-08-01), Husbands et al.
patent: 4824868 (1989-04-01), Watthey
patent: 4956388 (1990-09-01), Robertson et al.
patent: 4996235 (1991-02-01), Robertson et al.
patent: 5006525 (1991-04-01), Schaus
patent: 5013761 (1991-05-01), Beedle et al.
patent: 5023269 (1991-06-01), Robertson et al.
patent: 5057515 (1991-10-01), Schaus
patent: 5135947 (1992-08-01), Robertson et al.
Fontana et al., Psychopharmacology, 95:147-150 (1988).
Bodnoff et al., Psychopharmacology, 97:277-279 (1989).
Bodnoff et al., Psychopharmacology, 95:298-302 (1988).
Lydiard, J. Clin. Psychiatry, 52:6(suppl), Jun. 1991.
Rickels, et al., Arch. Gen. Psychiatry, vol. 50, Nov. 1993.
Kahn, et al., Arch. Gen Psychiatry, vol. 43, Jan. 1986.
Fonzo, et al., Acta Psychiatr Scand, 95:444-450, 1997.
Davies et al., The Journal of Nervous and Mental Disease, vol. 183, No. 1, 1995.
Rickels, et al., J. Clin. Psychiatry, 54:1 (suppl), Jan. 1993.
Anderson, et al., Am. J. Psychiatry 141:4, Apr. 1984.
Barlow, et al., Am. J. Psychiatry, 143:1, Jan. 1986.
Kahn, et al., Journal of Affective Disorders, 13, 145-151 (1987).
Brown, et al., Am. J. Psychiatry, 151:9, Sep. 1994.
Sanderson et al., The Journal of Nervous and Mental Disease, vol. 178, No. 9, 1990.
Wingerson et al., J. Clin. Psychopharmacology, vol. 12, No. 3, Jun. 1992.
Wilcox et al., Prog. Neuro-Psychopharmacol. & Biol. Psychiat, vol. 18, 979-993, 1994.
Hoehn-Saric et al., J. Clin. Psychiatry 49:8, Aug. 1988.
Shores et al., Comprehensive Psychiatry, vol. 33, No. 4, 237-244, 1992.
Rickels et al., JAMA, vol. 250, No. 6, Aug. 12, 1983.
Rickels et al., Arch. Gen. Psychiatry, vol. 45, May 1988.
Rickels et al., J. Clin. Psychopharmacology, vol. 10, No. 3, 1990.
Fluoxetine--A Review of Its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Efficacy in Depressive Illness. Drugs 32: 481-508 (1986), Benfield et al.
Serotonergic Mechanisms in the Behavioral Effects of Buspirone and Gepirone. Eison et al., Pharm. Bioch. and Behavior, vol. 24, pp. 701-707, 1986.
Dexfenfluramine--Its Place in Weight Control. Turner, Drugs 39 (Suppl. 3): 53-62, 1990.
Venlafaxine: A New Dimension in Antidepressant Pharmacology. Montgomery, J. Clin. Psychiatry 54:3, Mar. 1993.
Dexfenfluramine--A Review of Its Pharmacological Properties and Therapeutic Potential in Obesity, McTavish et al., Drugs 43(5): 713-733, 1992.
Appetite Suppressants--A Review. Silverstone, Drugs 43(6): 820-836, 1992.
Dosing Stragies for Antidepressant Agents. Schatzburg, J. Clin. Psychiatry 52:5 (suppl.), May 1991.
Fluoxetine: A Serotonergic Appetite Suppressant Drug. Fuller and Wong, Drug Development Research 17: 1-15 (1989).
2-Phenyl-2-(1-hydroxycycloalkyl)ethylamine Derivatives: Synthesis and Antidepressant Activity. Yardley et al., J. Med. Chem., 1990, 33.
Rudolph Richard L.
Upton G. Virginia
American Home Products Corporation
Eck Steven R.
Moezie M.
LandOfFree
Venlafaxine for the treatment of generalized anxiety disorder does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Venlafaxine for the treatment of generalized anxiety disorder, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Venlafaxine for the treatment of generalized anxiety disorder will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1375729